In this younger patient population, diazepam nasal spray was readily absorbed and demonstrated a consistent PK profile with that of older children and adults aged 6 to 59 years.

The company is developing psychedelics for depression, and hopes to go public within a year of its next published results, per documents seen by BI.

The US Food and Drug Administration (FDA) has approved Neurelis’ diazepam nasal spray, Valtoco, for the short-term treatment ...

Here's the lowdown from allergy doctors on how to get relief, from which medicines to use — and how to best use them — to ...